Another possible mechanism for orally administered statins retarding the pathologic process of disc degeneration

Medical Hypotheses

Volumn 76, Issue 2, 2011, Pages 302-303

  Hao, Yue Dong ^a   Yu, Guang Rong ^b   Liu, Yu Ping ^b  

^a Tongji University   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; CHONDROPROTECTION; CYTOKINE PRODUCTION; DRUG MECHANISM; HUMAN; INTERVERTEBRAL DISK DEGENERATION; LETTER; VASCULARIZATION;

ADMINISTRATION, ORAL; BONE MORPHOGENETIC PROTEIN 2; CARTILAGE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERVERTEBRAL DISK; INTERVERTEBRAL DISK DEGENERATION;

EID: 78651090514     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.11.009     Document Type: Letter

References (11)

1. Shi S., Wang C., Yuan W., Wang X., Zhou X. Potential prevention: Orally administered statins may retard the pathologic process of disc degeneration. Med Hypotheses 2011, 76:125-127.
2. Studer RK, Aboka AM, Gilbertson LG, Georgescu H, Sowa G, Vo N, Kang JD. p38 MAPK inhibition in nucleus pulposus cells: a potential target for treating intervertebral disc degeneration. Spine (Phila Pa 1976) 2007;32:2827-33.
3. Nerlich AG, Schleicher ED, Boos N. Immunohistologic markers for age-related changes of human lumbar intervertebral discs. Spine (Phila Pa 1976) 1997;22:2781-95 [Volvo award winner in basic science studies].
4. Moore RJ, Crotti TN, Osti OL, Fraser RD, Vernon-Roberts B. Osteoarthrosis of the facet joints resulting from anular rim lesions in sheep lumbar discs. Spine (Phila Pa 1976) 1999;24:519-25.
5. Barter M.J., Hui W., Lakey R.L., Catterall J.B., Cawston T.E., Young D.A. Lipophilic statins prevent matrix metalloproteinase-mediated cartilage collagen breakdown by inhibiting protein geranylgeranylation. Ann Rheum Dis 2011, 76:125-127.
6. Simopoulou T., Malizos K.N., Poultsides L., Tsezou A. Protective effect of atorvastatin in cultured osteoarthritic chondrocytes. J Orthop Res 2010, 28:110-115.
7. Akasaki Y., Matsuda S., Nakayama K., Fukagawa S., Miura H., Iwamoto Y. Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation. Osteoarthritis Cartilage 2009, 17:235-243.
8. Liu Y.P., Yu G.R. Comment on " The matrix metalloproteinases as pharmacological target in osteoarthritis: statins may be of therapeutic benefit" Med Hypotheses 2010, 74:394-395.
9. Tousoulis D., Andreou I., Tentolouris C., Antoniades C., Papageorgiou N., Gounari P. Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. Int J Cardiol 2009.
10. Peng B., Hou S., Shi Q., Jia L. The relationship between cartilage end-plate calcification and disc degeneration: an experimental study. Chin Med J (Engl) 2001, 114:308-312.
11. Zhang H., Wang L., Park J.B., Park P., Yang V.C., Hollister S.J. Intradiscal injection of simvastatin retards progression of intervertebral disc degeneration induced by stab injury. Arthritis Res Ther 2009, 11:R172.